EG 427 is a French biotechnology company that is pioneering a new approach called pinpoint gene therapy.
Our unique, non-replicative Herpes Simplex Virus type 1 (HSV-1) based vector platform delivers, with pinpoint precision, highly selective, durable expression of disease modifying transgenes for use in the treatment of peripheral nervous system disorders and beyond. Our research capability is focussed on ensuring our powerful platform approach has wide applicability, with potential for many products across several therapeutic areas with severe unmet medical needs.
Our first targets in the peripheral nervous system are Type C sensory neurons. Our lead asset, EG110A, targeting these neurons, is in preclinical development for the treatment of neurogenic bladder dysfunction, also called NDO. It is expected to be in the clinic by early 2024. Our revolutionary approach to the treatment of NDO aims to provide patients with a comprehensive, long-term solution to their bladder management, through a highly selective molecular surgery approach overcoming the significant drawbacks of the current standard of care.
Our HQ and labs are in Paris, France, where we were founded, in 2019, by a world-renowned team in the field of HSV-1 vectorology and spinal cord injury-related disorders.
Foundational research started in 2013 through a pan-European project including Universities in Versailles, France, Ferrara, Italy, and Madrid, Spain, with the goal, from the very beginning, to use the natural properties of HSV-1 as a gene therapy vector to treat neurogenic bladder disorder. This project was funded with over Euro 3 million by the European commission, the French government, SATT Paris-Saclay, and Wings for Life, a foundation dedicated to medical research on spinal cord associated diseases. EG 427 secured a worldwide exclusive license on all resulting Intellectual Property at inception of the company.
We have raised over USD 15 million, including from our Series A in 2021.
We believe that our uniquely flexible platform can be applied to multiple in vivo and ex vivo approaches and are looking to explore this potential through partnerships with the pharma and biotech industry.
Examples of possible indications connected to PNS: